Biotech and Pharmaceuticals Pharmaceuticals

  • Scott Knoer, Cleveland Clinic Chief Pharmacy Officer 160829

    Chief pharmacy officer at the Cleveland Clinic discusses Mylan's "generic" version of its own product, the Epipen, on CNBC's "Closing Bell."

  • Bullish bets on health care

    Brian Stutland, Equity Armor Investments CIO, shares his bullish take on the health care sector, amid all the political rhetoric surrounding Mylan. The "Fast Money" traders weigh in.

  • *Generic EpiPen to cost $300 vs branded price of about $600. Aug 29- Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen for $300, half the price of the branded product, the drugmaker's second step in less than a week to counter the backlash over the product's steep price. The company reduced the out-of-pocket costs of EpiPen...

  • *Generic EpiPen to cost $300 vs branded price of about $600. Aug 29- Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen for $300, half the price of the branded product, the drugmaker's second step in less than a week to counter the backlash over the product's steep price. The company reduced the out-of-pocket costs of EpiPen...

  • What's next for Mylan CEO?

    CNBC senior markets commentator Mike Santoli; and Susan Ochs, New America Foundation, discuss Mylan CEO Heather Bresch and the company's release of a generic EpiPen.

  • *Generic EpiPen to cost $300 vs branded price of about $600. Aug 29- Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen for $300, half the price of the branded product, the drugmaker's second step in less than a week to counter the backlash over the product's steep price. The company reduced the out-of-pocket costs of EpiPen...

  • Valeant Pharmaceuticals' chief executive Joseph Papa

    Valeant Pharmaceuticals International was sued on Monday by buyers of its drugs. The plaintiffs claim they were forced to pay exorbitant prices.

  • House committee sends letter to Mylan

    CNBC's Meg Tirrell reports that a House committee has sent a letter to Mylan for information on the EpiPen price increase.

  • US health care system needs more transparency: Pro

    Former FDA Deputy Commissioner Dr. Scott Gottlieb, who's with the American Enterprise Institute, discusses what's wrong with the US health care system.

  • SAN JUAN, Puerto Rico— A Pennsylvania drug company announced Monday that it has launched a clinical trial of an experimental Zika vaccine in Puerto Rico, the part of the U.S. hardest hit by the mosquito-borne virus. Inovio Pharmaceuticals Inc. will be testing its DNA-based vaccine candidate on 160 adult volunteers in Puerto Rico. "The rapid progression of the...

  • Healthcare

    Steve Brill, lawyer and author of "America's Bitter Pill: Money, Politics, Backroom Deals and the Fight to Fix our Broken Healthcare System" discusses what can be done to make things right with America's health care system.

  • Healthcare's best bets following generic EpiPen

    Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.

  • *Generic EpiPen to cost $300 vs branded price of about $600. Aug 29- Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen for $300, half the price of the branded product, the drugmaker's second step in less than a week to counter the backlash over the product's steep price. The company reduced the out-of-pocket costs of EpiPen...

  • Aug 29- Walgreens Boots Alliance Inc said it would partner with pharmacy benefit manager Prime Therapeutics to reduce drug procurement costs. The companies will combine their central specialty pharmacy and mail order service businesses and introduce a new retail pharmacy network that will give Prime Therapeutics' customers access to Walgreens' pharmacy...

  • *Generic EpiPen to cost $300 vs branded price of about $600. The company reduced the out-of-pocket costs of EpiPen for some patients last week, but kept the list price at about $600, a move that U.S. lawmakers and Presidential candidate Hillary Clinton said was not enough. Chief Executive Heather Bresch has defended EpiPen's high price, saying Mylan had spent...

  • Stocks to Watch: August 29, 2016

    Mylan, Herbalife and T-Mobile are making headlines this Monday morning.

  • *Generic EpiPen to cost $300 vs branded price of about $600. The company reduced the out-of-pocket costs of EpiPen for some patients last week, but kept the list price at about $600, a move that lawmakers said was not enough. Chief Executive Heather Bresch has defended EpiPen's high price, saying Mylan had spent hundreds of millions of dollars improving the...

  • Mylan to sell cheaper generic EpiPen

    The pharmaceutical company will offer patients a two-pack carton at half price of the branded version.

  • Mylan said it expected to launch the generic product "in several weeks" at a list price of $300. The branded product costs about $600. Valeant Pharmaceuticals International Inc and privately held Turing Pharmaceuticals have both been publicly excoriated for similar price increases.

  • Despite its second move in five days to make EpiPens more affordable for consumers, maker Mylan N.V. still faces condemnation from critics who accused it of price-gouging. Richard Blumenthal, D- Connecticut, said in a statement Monday. Mylan, which mainly sells generic medicines, said Monday it will begin selling its generic version for $300 for a pair of EpiPens,...